5:33 AM
Nov 06, 2018
 |  BC Extra  |  Company News

Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214

Pfizer Inc. (NYSE:PFE) will combine NKTR-214 from Nektar Therapeutics Inc. (NASDAQ:NKTR) with the pharma's marketed drugs Xtandi enzalutamide, Talzenna talazoparib and Bavencio avelumab to treat prostate cancer, testing the biotech's hypothesis that stimulation of IL-2 alongside these other MOAs in tumors with a high mutational burden could provide synergistic benefits.

Financial terms for the clinical collaboration are not disclosed, but Pfizer will test triplet combinations of NKTR-214 with anti-PD-L1 drug Bavencio and either Talzenna or Xtandi in metastatic castration-resistant prostate cancer (mCRPC).

The rationale behind the triplet combinations is to build upon the immune response initiated by monotherapy with Talzenna, a PARP inhibitor, or Xtandi, an androgen receptor...

Read the full 524 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD